"Planeterranean" Diet: Globally Extending the Health Benefits of the Mediterranean Diet | |
Fibrosis and Cancer Intersection |
Call for papers
Regeneration and Remodeling after Brain Injury: Implications for Stem Cell Therapy
We are welcoming submissions to our new collection on Regeneration and Remodeling after Brain Injury, guested edited by Hailiang Tang and Francisco Silva.
Submission Deadline: 25 June 2025
Prevention and Early Diagnosis of Breast Cancer
We are welcoming submissions to our new collection on prevention and early diagnosis of breast cancer, guested edited by Monica Pernia Marin, Caren Greenstein, and Mary Salvatore.
Submission Deadline: 27 February 2025
© Dr Erica Tandori
Molecular mimicry in human diseases
We are welcoming submissions to our new collection on molecular mimicry in human diseases, guested edited by Luigi Buonaguro and Jamie Rossjohn.
Submission Deadline: 15 December 2024
Article Collections
Join the Editorial Board
We are recruiting new Associate Editors to join our international Editorial Board. Learn more about the role and how to apply here.
Meet the Editors
Get to know the Editors behind Journal of Translational Medicine!
Journal of Precision Health: Editor-in-Chief
We are pleased to announce the upcoming launch of Journal of Precision Health, which will be a companion title to Journal of Translational Medicine.
We are seeking to appoint and Editor-in-Chief to lead Journal of Precision Health, and more information about the position and how to apply can be found here.
Closing date for applications: 13 October 2024
Articles
-
-
Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis
-
Targeting CD276 for T cell-based immunotherapy of breast cancer
-
Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment
-
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer
-
Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey
-
Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males
-
Why tocilizumab could be an effective treatment for severe COVID-19?
-
Influence of diet on the gut microbiome and implications for human health
-
Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage
Featured Research: DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models
Delta-like ligand 3 (DLL3) is highly expressed on the cell surface of small cell lung cancer (SCLC), one of the most lethal malignancies, but minimally or not in normal tissues, making it an attractive target for SCLC. However, none of the DLL3-targeting antibody-drug conjugates (ADCs) have been approved for SCLC therapy yet. We developed DB-1314, the new anti-DLL3 ADC composed of a novel humanized anti-DLL3 monoclonal antibody (DB131401) conjugated with eight molecules of P1021 (topoisomerase I inhibitor), and described its preclinical profiles.
Featured Review: Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy
Asthma poses a major public health burden. While existing asthma drugs manage symptoms for many, some patients remain resistant. The lack of a cure, especially for severe asthma, compels exploration of novel therapies. Cancer immunotherapy successes with CAR-T cells suggest its potential for asthma treatment. This review will delve into the evolution and production of CAR designs, explore pre-clinical and clinical studies of CAR-based therapies in asthma, analyze strategies to optimize CAR-NK cell function, conduct a comparative analysis of CAR-T and CAR-NK cell therapy with their respective challenges, and finally present established novel CAR designs with promising potential for asthma treatment.
Introducing new sections to Journal of Translational Medicine!
Regenerative Medicine
Led by Section Editor Francisco Silva, the Regenerative Medicine section aims to bring together experts across research disciplines (such as biology, chemistry, computer science, engineering, genetics, medicine, and robotics) in order to find new solutions towards therapies. The clinically disruptive field of regenerative medicine encompasses various strategies including the use of materials and biologics to take the place or remodel compromised tissues both structurally and functionally in order to facilitate tissue healing.
The section welcomes research focused on advancing the various technologies that encompass regenerative medicine to aid in the development and translation of novel therapies for those suffering from unmet medical needs.
Molecular Pathology
Led by Section Editor Sarah Warren, the Molecular Pathology section aims to highlight studies that characterize human-derived biological materials, including both tissue and liquid biopsies, using molecular profiling techniques to elucidate the underlying causes of disease and impacts of therapeutic interventions.
The Molecular Pathology section will consider studies that are preclinical or translational in nature, as well as from all stages of fundamental and applied research. The section welcomes manuscripts that describe new technology platforms that advance molecular profiling or novel computational approaches to support data analysis.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreTop trending articles
Check out the most discussed articles from the previous month!
Featured section: Neuroscience
The Neuroscience section aims to encourage publications that help to reduce the gap between basic preclinical science and medical applications for the patients in the neuroscience field. Any new tool for the dissemination of results in the field can greatly help to progress in the new solutions for the neuropsychiatric patient. The section aims to promote the increase of knowledge on the subject by publishing original research.
Editor-in-Chief: Francesco Marincola, Sonata Therapeutics, USA
Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.
Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.
Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.
Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.
Franco received his M.D. from the University of Milan and completed his residency at Stanford University.
Aims and scope
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
|
|
|
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 6.1
5-year Journal Impact Factor: 6.2
Source Normalized Impact per Paper (SNIP): 1.234
SCImago Journal Rank (SJR): 1.611Speed 2023
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 86Usage 2023
Downloads: 4,999,990
Altmetric mentions: 8,678